

Lupin launches generic drug in US

New Delhi: Drug firm Lupin Ltd has launched its generic Ciprofloxacin, used for treating bacterial infections, in the American market and is expecting 180 days of market exclusivity. The company's US subsidiary, Lupin Pharmaceuticals Inc (LPI) has launched its Ciprofloxacin for oral suspension in the US market in the strengths of 5 g/100 mL (250mg/5 mL) and 10 g/100 mL (500 mg/5 mL), Lupin said. LPI had earlier received final approval for the product from the USFDA, it added. "Lupin is the first applicant to file an ANDA for Cipro oral suspension in 250 mg/ml and 500 mg/ml," the company said. — PTI

Company